A turning point in COVID-19 severity and fatality during the pandemic: A national cohort study in Qatar
暂无分享,去创建一个
Gheyath K Nasrallah | R. Bertollini | M. Al-Kuwari | H. Yassine | Z. Al-Kanaani | A. Butt | H. Al-Romaihi | A. Jeremijenko | A. Latif | H. Chemaitelly | H. Ayoub | P. Tang | M. Hasan | H. Al-Khatib | P. Coyle | E. Al-Kuwari | A. Kaleeckal | R. Shaik | H. Abdul-Rahim | L. Abu-Raddad | A. Al-khal | L. Abu‐Raddad | J. Faust | A. Althani | M. H. Al-Thani | A. Al-Khal | M. Al-Thani
[1] L. Abu-Raddad,et al. All-cause and COVID-19 mortality in Qatar during the COVID-19 pandemic , 2023, BMJ Global Health.
[2] A. Sodickson,et al. Prevalence of Pneumonia Among Patients Who Died with COVID-19 Infection in Ancestral Versus Omicron Variant Eras , 2023, Academic Radiology.
[3] Gheyath K Nasrallah,et al. Population immunity of natural infection, primary-series vaccination, and booster vaccination in Qatar during the COVID-19 pandemic: an observational study , 2023, medRxiv.
[4] Gheyath K Nasrallah,et al. Effects of previous infection, vaccination, and hybrid immunity against symptomatic Alpha, Beta, and Delta infections , 2023, medRxiv.
[5] Gheyath K Nasrallah,et al. Bivalent mRNA-1273.214 vaccine effectiveness in Qatar , 2023, medRxiv.
[6] Gheyath K Nasrallah,et al. Short- and longer-term all-cause mortality among SARS-CoV-2- infected persons and the pull-forward phenomenon in Qatar , 2023, medRxiv.
[7] Gheyath K Nasrallah,et al. Protection against Reinfection with the Omicron BA.2.75 Subvariant , 2023, The New England journal of medicine.
[8] J. Wakefield,et al. The WHO estimates of excess mortality associated with the COVID-19 pandemic , 2022, Nature.
[9] Gheyath K Nasrallah,et al. Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study , 2022, The Lancet Infectious Diseases.
[10] Gheyath K Nasrallah,et al. Protective Effect of Previous SARS-CoV-2 Infection against Omicron BA.4 and BA.5 Subvariants , 2022, The New England journal of medicine.
[11] L. Abu-Raddad,et al. COVID-19 Disease Severity in Persons Infected With Omicron BA.1 and BA.2 Sublineages and Association With Vaccination Status. , 2022, JAMA internal medicine.
[12] Shu-Xia Li,et al. Uncoupling of all-cause excess mortality from COVID-19 cases in a highly vaccinated state , 2022, The Lancet Infectious Diseases.
[13] L. Abu-Raddad,et al. COVID-19 disease severity in persons infected with the Omicron variant compared with the Delta variant in Qatar , 2022, Journal of global health.
[14] Gheyath K Nasrallah,et al. Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections , 2022, The New England journal of medicine.
[15] J. Malek,et al. Application of human RNase P normalization for the realistic estimation of SARS-CoV-2 viral load in wastewater: A perspective from Qatar wastewater surveillance , 2022, Environmental Technology & Innovation.
[16] L. Abu-Raddad,et al. Assessing vaccine effectiveness against severe COVID-19 disease caused by omicron variant. Report from a meeting of the World Health Organization , 2022, Vaccine.
[17] L. Abu-Raddad,et al. Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild-to-moderate SARS-CoV-2 in Qatar , 2022, International Journal of Infectious Diseases.
[18] Gheyath K Nasrallah,et al. Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar , 2022, Nature Communications.
[19] Gheyath K Nasrallah,et al. Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar , 2022, The New England journal of medicine.
[20] Gheyath K Nasrallah,et al. Effects of BA.1/BA.2 subvariant, vaccination and prior infection on infectiousness of SARS-CoV-2 omicron infections , 2022, medRxiv.
[21] Reed J. D. Sorensen,et al. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21 , 2022, The Lancet.
[22] Gheyath K Nasrallah,et al. Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage , 2022, Nature Communications.
[23] Gheyath K Nasrallah,et al. Protection against the Omicron Variant from Previous SARS-CoV-2 Infection , 2022, The New England journal of medicine.
[24] S. Pilz,et al. SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity , 2022, Environmental Research.
[25] L. Abu-Raddad,et al. Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar , 2022, The New England journal of medicine.
[26] L. Abu-Raddad,et al. Efficacy of Natural Immunity against SARS-CoV-2 Reinfection with the Beta Variant , 2021, The New England journal of medicine.
[27] Gheyath K Nasrallah,et al. Introduction and expansion of the SARS-CoV-2 B.1.1.7 variant and reinfections in Qatar: A nationally representative cohort study , 2021, PLoS medicine.
[28] L. Abu-Raddad,et al. Severity of SARS-CoV-2 Reinfections as Compared with Primary Infections , 2021, The New England journal of medicine.
[29] L. Abu-Raddad,et al. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar , 2021, Nature Medicine.
[30] L. Abu-Raddad,et al. SARS-CoV-2 infection hospitalization, severity, criticality, and fatality rates in Qatar , 2021, Scientific Reports.
[31] L. Abu-Raddad,et al. Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar , 2021, medRxiv.
[32] L. Abu-Raddad,et al. Real-Time SARS-CoV-2 Genotyping by High-Throughput Multiplex PCR Reveals the Epidemiology of the Variants of Concern in Qatar , 2021, medRxiv.
[33] Gheyath K Nasrallah,et al. mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar , 2021, Nature Medicine.
[34] J. Malek,et al. One Year of SARS-CoV-2: Genomic Characterization of COVID-19 Outbreak in Qatar , 2021, Frontiers in Cellular and Infection Microbiology.
[35] L. Abu-Raddad,et al. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants , 2021, The New England journal of medicine.
[36] Gheyath K Nasrallah,et al. SARS-CoV-2 Infection Is at Herd Immunity in the Majority Segment of the Population of Qatar , 2021, Open forum infectious diseases.
[37] L. Abu-Raddad,et al. Herd Immunity against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 10 Communities, Qatar , 2021, Emerging infectious diseases.
[38] Gheyath K Nasrallah,et al. SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy , 2021, EClinicalMedicine.
[39] C. Vogels. Multiplexed RT-qPCR to screen for SARS-COV-2 B.1.1.7, B.1.351, and P.1 variants of concern v3 , 2021 .
[40] Oluwaseun O. Ogunbiyi,et al. COVID-19 (SARS-CoV-2) outbreak monitoring using wastewater-based epidemiology in Qatar , 2021, Science of The Total Environment.
[41] L. Abu-Raddad,et al. Estimates of global SARS-CoV-2 infection exposure, infection morbidity, and infection mortality rates in 2020 , 2021, Global Epidemiology.
[42] L. Summers,et al. The COVID-19 Pandemic and the $16 Trillion Virus. , 2020, JAMA.
[43] R. Bertollini,et al. Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic , 2020, Scientific Reports.
[44] C. Y. Li,et al. A review of the healthy worker effect in occupational epidemiology. , 1999, Occupational medicine.
[45] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .